You are here

Article Text

Article menu
Download PDFPDF
Letter
Palliation of malignancies in HIV infection
  1. Faiza Yasin1,2,
  2. Ronald Chow1,
  3. Brinda Emu1,
  4. Trinh Bui3 and
  5. Elizabeth Prsic1
  1. 1Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
  2. 2One Medical, San Francisco, California, USA
  3. 3Department of Pharmacy Services, Yale New Haven Hospital, Smilow Cancer Center, New Haven, Connecticut, USA
  1. Correspondence to Dr Faiza Yasin, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA; faiza.t.yasin{at}gmail.com

https://doi.org/10.1136/bmjspcare-2021-003179

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    It is important to consider medication interactions and overlapping medication toxicities in persons living with HIV (PLWH) who are on combination antiretroviral therapy (cART), in addition to disease-specific cancer therapy, medications to alleviate cytotoxic effects of chemotherapy, prophylaxis to prevent infection or medications for palliation.

    Protease inhibitors, integrase inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs) and non-NRTIs are the major components of commonly used cART regimens, and are metabolised via the cytochrome P450 (CYP450) system of the liver. Many antineoplastic agents, and supportive therapies, including those medications required for management of opportunistic infections (anti-infective medications including antifungal agents and antibiotics), nausea/vomiting (antiemetics and steroids), cancer-related pain (opioid analgesics) and comorbid psychiatric disorders (selective-serotonin …

    View Full Text

    Footnotes

    • Twitter @ElizabethPrsic

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.